ClinicalTrials.gg
CompletedNCT01174030Updated Feb 26, 2021Results posted

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Phase 2 interventional study of CD07805/47 Gel and Vehicle Gel in Rosacea, sponsored by Galderma R&D. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
4th of 11
269 · median 205
Started
2010
the only one that year
Phase 2
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 3rd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, who is at least 18 years of age or older.
  • A clinical diagnosis of rosacea.
  • A Clinician Erythema Assessment (CEA) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
  • A Patient Self Assessment-5 (PSA-5) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
  • A Patient Self Assessment-11 (PSA-11) score of 5 at Screening and at Pre-dose (T0) on Baseline/Day 1.

Exclusion criteria

Exclusion Criteria:

  • Three (3) or more facial inflammatory lesions.
  • Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.
  • Known allergies or sensitivities to any components of the study medications, including the active gel ingredient, brimonidine tartrate.
  • Intraocular pressure (IOP) measurement less than 10 mm Hg.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    CD07805/47 Gel 0.5% QD

    Drug: CD07805/47 Gel

  • Experimental
    CD07805/47 Gel 0.18% QD

    Drug: CD07805/47 Gel

  • Experimental
    CD07805/47 Gel 0.18% BID

    Drug: CD07805/47 Gel

  • Placebo comparator
    Vehicle Gel QD

    Drug: Vehicle Gel

  • Placebo comparator
    Vehicle Gel BID

    Drug: Vehicle Gel

Interventions

  • DrugCD07805/47 Gel

    Drug page: Brimonidine

    CD07805/47 Gel 0.5% QD

  • DrugVehicle Gel

    Vehicle Gel QD

  • DrugCD07805/47 Gel

    Drug page: Brimonidine

    CD07805/47 Gel 0.18% QD

  • DrugCD07805/47 Gel

    Drug page: Brimonidine

    CD07805/47 Gel 0.18% BID

  • DrugVehicle Gel

    Vehicle Gel BID

06

What researchers measure

Primary outcomes

  1. Composite Success

    Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5). Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.

    Time frame: Day 29

Secondary outcomes

  1. CEA Success

    CEA success defined as 2-grade improvement on CEA. Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Amost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness

    Time frame: Day 29

  2. PSA-5 Success

    Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. PSA-5 success defined as 2-grade improvement on PSA-5. Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness 1. / Very mild redness 2. / Mild redness 3. / Moderate redness 4. / Severe redness

    Time frame: day 29

07

Results

Posted Mar 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Started5354545553
Completed5152525352
Not completed22221

Outcome measures

PrimaryComposite Success

Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5). Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.

Time frame:
Day 29
Reported as:
Number · participants
Composite Success
participantsCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Day 29/Hour 316101024
Day 29/Hour 61510947
Day 29/Hour 917711210
Day 29/Hour 12105829
Statistical analysis
  • CD07805/47 Gel 0.5% QD vs Vehicle Gel QD · GEE:Logit link function · p = <0.001 · Odds ratio (or): 8.392 · 95% CI 2.637 to 26.710Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
  • CD07805/47 Gel 0.18% BID vs Vehicle Gel BID · GEE:Logit link function · p = 0.549 · Odds ratio (or): 1.269 · 95% CI 0.586 to 2.747Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
  • CD07805/47 Gel 0.18% QD vs Vehicle Gel QD · GEE:Logit link function · p = 0.027 · Odds ratio (or): 3.738 · 95% CI 1.097 to 12.742Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
SecondaryCEA Success

CEA success defined as 2-grade improvement on CEA. Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Amost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness

Time frame:
Day 29
Reported as:
Number · participants
CEA Success
participantsCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Day 29/Hour 3272122129
Day 29/Hour 62321181212
Day 29/Hour 92620231215
Day 29/Hour 122017181216
Statistical analysis
  • CD07805/47 Gel 0.5% QD vs Vehicle Gel QD · GEE:Logit link Function · p = .003 · Odds ratio (or): 2.683 · 95% CI 1.388 to 5.188Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model
  • CD07805/47 Gel 0.18% BID vs Vehicle Gel BID · GEE: Logit link Function · p = 0.056 · Odds ratio (or): 1.892 · 95% CI 0.980 to 3.651Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
  • CD07805/47 Gel 0.18% QD vs Vehicle Gel QD · GEE:Logit link Function · p = 0.074 · Odds ratio (or): 1.885 · 95% CI 0.946 to 3.756Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
SecondaryPSA-5 Success

Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. PSA-5 success defined as 2-grade improvement on PSA-5. Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness 1. / Very mild redness 2. / Mild redness 3. / Moderate redness 4. / Severe redness

Time frame:
day 29
Reported as:
Number · participants
PSA-5 Success
participantsCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Day 29/Hour 3251720711
Day 29/Hour 6261315811
Day 29/Hour 922919513
Day 29/Hour 1220916510
Statistical analysis
  • CD07805/47 Gel 0.5% QD vs Vehicle Gel QD · GEE: Logit link function · p = <0.001 · Odds ratio (or): 6.582 · 95% CI 2.755 to 15.723Generalize Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
  • CD07805/47 Gel 0.18% BID vs Vehicle Gel BID · GEE: Logit link function · p = 0.093 · Odds ratio (or): 1.853 · 95% CI 0.903 to 3.802Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.
  • CD07805/47 Gel 0.18% QD vs Vehicle Gel QD · GEE: Logit link function · p = 0.054 · Odds ratio (or): 2.365 · 95% CI 0.960 to 5.825Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD07805/47 Gel 0.5% QD—0/53 (0%)18/53 (34%)
CD07805/47 Gel 0.18% QD—1/54 (1.9%)13/54 (24.1%)
CD07805/47 Gel 0.18% BID—0/54 (0%)14/54 (25.9%)
Vehicle Gel QD—1/55 (1.8%)16/55 (29.1%)
Vehicle Gel BID—0/53 (0%)8/53 (15.1%)
Most frequent serious events
Most frequent serious events
EventCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Gastric RefluxGastrointestinal disorders0/531/540/540/550/53
Deep Vein ThrombosisVascular disorders0/530/540/541/550/53
Most frequent other events
Most frequent other events
EventCD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BID
Intraocular pressure increasedEye disorders7/536/548/549/554/53
FlushingVascular disorders4/531/540/540/550/53
HeadacheNervous system disorders4/533/543/541/550/53
PruritusSkin and subcutaneous tissue disorders3/533/541/544/550/53
Skin Burning SensationSkin and subcutaneous tissue disorders3/531/542/541/550/53
Skin WarmSkin and subcutaneous tissue disorders3/530/541/540/550/53
SinusitisInfections and infestations0/531/540/542/553/53
NasopharyngitisInfections and infestations2/530/541/543/551/53

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BIDTotal
<=18 years000000
Between 18 and 65 years5250505451257
>=65 years1441212
Age, Continuous
Age, Continuous(years)CD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BIDTotal
Mean44.9 ± 11.5046.9 ± 12.7243.2 ± 12.2843.4 ± 12.7343.0 ± 12.3344.3 ± 12.32
Sex: Female, Male
Sex: Female, Male(Participants)CD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BIDTotal
Female4244424544217
Male11101210952
Region of Enrollment
Region of Enrollment(participants)CD07805/47 Gel 0.5% QDCD07805/47 Gel 0.18% QDCD07805/47 Gel 0.18% BIDVehicle Gel QDVehicle Gel BIDTotal
United States5354545553269
08

Study locations

20 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • University of California at San Francisco
    San Francisco, California 94143-0660, United States
  • Meda Phase, Inc
    Newnan, Georgia 30263, United States
  • Dermatology Specialists PC
    Louisville, Kentucky 40202, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Central Dermatology, PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialty Group
    New York, New York 10021, United States
  • Dermatology Laser & Vein Specialists
    Charlotte, North Carolina 28207, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Oregon Dermatology & Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research
    Portland, Oregon 97223, United States
  • Philadelphia Institute of Dermatology
    Fort Washington, Pennsylvania 19034, United States
  • DermDox
    Hazleton, Pennsylvania 18201, United States
  • Palmetto Clinical Trial Services, LLC
    Greenville, South Carolina 29007, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37902, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Dermatology Treatment & Research Center
    Dallas, Texas 75230, United States
  • The Education & Research Foundation
    Lynchburg, Virginia 24501, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
  • Madison Skin & Research
    Madison, Wisconsin 53719, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Dec 2010 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 3 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2010
First posted
Aug 3, 2010
Start
Aug 2010
Primary completionActual
Dec 2010
CompletionActual
Jan 2011
Results delay requested
Jun 6, 2011
Results first posted
Mar 11, 2014
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01174030
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Aug 3, 2010
Start date
Aug 2010
Primary completion
Dec 2010
Completion
Jan 2011
Results posted
Mar 11, 2014
Last update
Feb 26, 2021

Study contacts

Michael Graeber, MD
study director · Galderma R&D, Inc
William Abramovits, MD
principal investigator · Dermatology Treatment & Research Center
Fran Cook-Bolden, MD
principal investigator · Skin Specialty Group
Zoe Draelos, MD
principal investigator · Dermatology Consulting Services, High Point NC
Joseph Fowler, MD
principal investigator · Dermatology Specialists, PSC
Kimberly Grande, MD
principal investigator · The Skin Wellness Center
Michael Heffernan, MD
principal investigator · Central Dermatology PC
Steven Kempers, MD
principal investigator · Minnesota Clinical Study Center
Mark Ling, MD
principal investigator · Meda Phase, Inc.
Robert Matheson, MD
principal investigator · Oregon Medical Research
Kappa Meadows, MD
principal investigator · The Education & Research Foundation
Angela Moore, MD
principal investigator · Arlington Center for Dermatology
Girish Munavalli, MD
principal investigator · Dermatology, Laser & Vein Specialists of the Carolinas
Andrew Pollack, MD
principal investigator · Philadelphia Institute of Dermatology
Phoebe Rich, MD
principal investigator · Oregon Dermatology & Research Center
Harry Sharta, MD
principal investigator · Madison Skin & Research
Martin Steinhoff, MD
principal investigator · University of California at San Francisco
Dow Stough, MD
principal investigator · Burke Pharmaceutical Research
William Werschler, MD
principal investigator · Premier Clinical Research
Patricia Westmoreland, MD
principal investigator · Palmetto Clinical Trial Services, LLC
Stephen Schleicher, MD
principal investigator · DermDox

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion